The recombinant, humanized monoclonal antibody Herceptin is administered as an initial 4 mg/kg i.v. infusion over 90 min, followed by weekly 2 mg/kg i.v. infusions over 30 min. In pivotal clinical trials Herceptin, both as a single agent and in combination with chemotherapy, was found to produce a significant survival benefit in @entity1722 -positive metastatic @entity0 @entity1 . Importantly, Herceptin was well tolerated and was not associated with a poor side-effect profile, producing mainly mild to moderate side-effects. These were generally associated with the initial infusion. The incidence of adverse events was low with Herceptin therapy and severe @entity391 and alopecia, typical of many chemotherapy treatment regimens, were not experienced by @entity1 in the trials. @entity299 was the most significant Herceptin-related adverse event but could, in most cases, be managed using standard therapy. The favourable adverse event profile seen with Herceptin is reflected in the quality of life (QoL) data. The health-related QoL of @entity1 receiving Herceptin therapy alone or in combination with chemotherapy was found to be maintained. Previous studies have noted a deterioration of health-related QoL in @entity1 treated with chemotherapy only. Thus, as well as providing significant survival benefit, Herceptin therapy improves @entity1 well being.

Anti- XXXX therapy: how to use Herceptin in clinical practice.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity299 :: ('MESH:D006331', 'Disease') :: ['Cardiac dysfunction'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1722 :: (2064,Gene) :: ['HER2']
